Patient Case Studies and Panel Discussion: Management of Acute Lymphoblastic Leukemia
It is critically important for oncology care providers to be aware of the best ways to incorporate these advances into standard practice so that each patient can receive optimal care.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
New Treatment Options and Toxicity Management in Acute Lymphoblastic Leukemia
Newer agents used in the treatment of acute lymphoblastic leukemia (ALL) have led to improved clinical outcomes, but are associated with significant toxicities. Clinicians need to be educated on appropriate management approaches for the side effects associated with these new therapies to allow patients to receive maximal benefit and optimal care.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Familial/Genetic Leukemia Syndromes: Impact on Patient Care
Clinicians need education regarding which patients with leukemia are candidates for genetic counseling and testing and how the management of patients with known germline mutations is affected. This knowledge will help clinicians provide these patients with optimal care.
Category
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Chronic Myelogenous Leukemia
  • Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy
Consolidation therapy is a critical component of ALL therapy, with the goal of eliminating any leukemic cells potentially remaining after induction therapy, further eradicating residual disease. MRD assessment is an essential component of the evaluation of response to therapy in ALL.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Case Studies in the Management of Leukemia
As a result of the therapeutic advances and clinical research affecting the management of patients with leukemia, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
Category
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
NCCN Pharmacy Updates: Updates in the Treatment of Adult Acute Lymphoblastic Leukemia
Side effects of novel therapies may be severe. Cytokine release syndrome, neurotoxicity, and sinusoidal obstruction syndrome (SOS/VOD) are just some of the serious adverse effects that may occur. With the expanding roles of monoclonal antibodies and CAR-T therapies in acute lymphoblastic leukemia (ALL), pharmacists should be aware of their proper place in therapy and side effect management for patient safety.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date December 20, 2023